Brief: Eisai: To Discontinue Administration Of Anticancer Agent EZH2 Inhibitor Tazverik Tablets 200 Mg Manufactured And Marketed In Japan
19/03/2026 05:33
March 19 (Reuters) - Eisai Co Ltd 4523.T: EISAI: TO DISCONTINUE ADMINISTRATION OF ANTICANCER AGENT EZH2 INHIBITOR TAZVERIK TABLETS 200 MG MANUFACTURED AND MARKETED IN JAPAN Source text: https://www.eisai.com/news/2026/pdf/enews202615pdf.pdf Further company coverage: 4523.T (Reporting by Kantaro Komiya) ((Kantaro.Komiya@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China